Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.
Market Cap | 668.133 Million | Shares Outstanding | 77.962 Million | Avg 30-day Volume | 1.278 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.17 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -55.214 Million |
Price to Book Value | 5.3475 | Operating Margin | 0.0 | Enterprise Value | 578.956 Million |
Current Ratio | 12.032 | EPS Growth | 0 | Quick Ratio | 11.647 |
1 Yr BETA | 1.9782 | 52-week High/Low | 15.24 / 7.13 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -1.991 | Altman Z-Score | 30.1586 | Free Cash Flow to Firm | -34.533 Million |
Earnings Report | 2023-05-10 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
50,000 | 2022-06-27 | 2 | |
|
50,000 | 2022-06-27 | 1 | |
|
50,000 | 2022-06-27 | 1 | |
|
50,000 | 2022-06-27 | 1 | |
|
50,000 | 2022-06-27 | 1 | |
MISSLING CHRISTOPHER U CHIEF EXECUTIVE OFFICER |
|
500,000 | 2021-08-02 | 0 |
BOENISCH SANDRA PFO AND TREASURER |
|
40,000 | 2021-08-02 | 0 |
|
0 | 2021-05-21 | 0 | |
|
0 | 2016-09-22 | 0 | |
LALACH HARVEY PRESIDENT COO SECRETARY |
|
1,118,572 | 2012-05-24 | 0 |
TIDMARSH GEORGE F EXECUTIVE DIRECTOR |
|
512,000 | 2012-02-09 | 0 |
|
0 | 2011-05-13 | 0 | |
|
0 | 2011-02-24 | 0 | |
DURRANT CAMERON EXECUTIVE CHAIRMAN |
|
0 | 2011-02-03 | 0 |
|
0 | 2010-09-01 | 0 | |
|
0 | 2010-06-29 | 0 | |
|
0 | 2009-06-12 | 0 | |
WU PEI RU COO |
|
0 | 2006-04-25 | 0 |
WU YANG PRESIDENT & CEO |
|
0 | 2006-04-25 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 22:15:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 21:45:05 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 21:15:03 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 20:45:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 20:15:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 19:45:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 19:15:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 18:45:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 18:15:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 17:45:04 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 17:15:03 UTC | 3.7377 | 1.0823 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 16:45:04 UTC | 3.7427 | 1.0773 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 16:15:04 UTC | 3.7427 | 1.0773 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 15:45:04 UTC | 3.7427 | 1.0773 | 150000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 15:15:03 UTC | 3.7427 | 1.0773 | 250000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 14:45:04 UTC | 3.7427 | 1.0773 | 250000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 14:15:04 UTC | 3.7427 | 1.0773 | 250000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 13:45:03 UTC | 3.4725 | 1.3475 | 250000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 13:15:03 UTC | 3.4725 | 1.3475 | 250000 |
ANAVEX LIFE SCIENCES CORP AVXL | 2023-03-31 12:45:03 UTC | 3.4725 | 1.3475 | 250000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | AVXL | -1341.0 shares, $-12417.66 | 2022-12-31 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | AVXL | -6131.0 shares, $-66643.97 | 2023-01-31 | N-PORT |
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
![]() |
Hon. Christopher L. Jacobs | republican | House | Filing | 2023-01-10 | 2022-12-12 | S | $1,001-$15,000 | ||
![]() |
Hon. Christopher L. Jacobs | republican | House | Filing | 2022-11-11 | 2022-10-12 | P | $1,001-$15,000 |